Private equity firm 21 Partners has agreed to acquire Synerlab from Ardian.
The transaction will be executed alongside Synerlab’s management team, led by its president Pierre Banzet.
Ardian will subsequently reinvest in the company in order to support Synerlab with its pan-European development, together with 21 Partners.
Synerlab is a pharmaceutical contract manufacturing firm and a European leader in the production of sterile liquid solutions which do not use preserving agents. The company has expertise in small- to large-size industrial production.
The group has a particular focus on R&D, enabling it to support its clients through the pharmaceutical development and formulation process. The group has more than 600 employees across four production sites and one R&D centre, all based in France.
21 Partners and Ardian, the historical shareholders which entered the capital of Synerlab in 2007, will provide their combined expertise to support the growth strategy of the group, which will include expanding into new markets, market consolidation in Europe and organic growth.
Banzet says: “The management team and I are delighted with the partnership between 21 Partners and Ardian, who will both provide us with the networks and support which will allow our group to enter a new stage of development.”
Gérard Pluvinet, founding managing partner of 21 Partners, says: “We completely share the strategic view of Pierre Banzet and his team. We are excited to support them in their ambitious development plan within the European markets.”
Francois Jerphagnon, managing director small market enterprise capital at Ardian, says: “After a successful six year partnership with Synerlab’s management team, in which Synerlab has strengthened its position with three build-ups, we are pleased to extend this partnership for this new stage of structural development.”
